

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has four novel and differentiated drug development programs. OLINVYK® is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at [OLINVYK.com](https://www.olinvyk.com). The company has three investigational drug candidates, including TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. The company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating diabetic neuropathic pain, epilepsy, and other CNS disorders.

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

Apr 1 2024, 7:00 AM EDT

Trevena Announces the Closing of \$4 Million Concurrent Private Placement and Warrant Exercise

Dec 28 2023, 2:00 PM EST

Trevena Inc. Announces \$4 Million Concurrent Private Placement and Warrant Exercise

Dec 27 2023, 9:10 AM EST

Stock Overview

Symbol	TRVN
Exchange	Nasdaq
Market Cap	7.18m
Last Price	\$0.39
52-Week Range	\$0.30 - \$3.28

04/15/2024 03:55 PM EDT

Trevena, Inc.

955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.